Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma

Data comparing HLA-haploidentical donors and HLA-matched sibling donors (MSDs) in peripheral blood stem cell transplantation (PBSCT) for lymphoma are scarce. We retrospectively analyzed 465 patients with lymphoma aged 16 years or older who underwent PBSCT using haploidentical donors with post-transp...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2024-05, Vol.59 (5), p.630-636
Main Authors: Nakaya, Yosuke, Nakamae, Hirohisa, Nishikubo, Masashi, Kondo, Eisei, Fukuda, Takahiro, Hiramoto, Nobuhiro, Mori, Yasuo, Nagafuji, Koji, Eto, Tetsuya, Onishi, Yasushi, Uchida, Naoyuki, Ishikawa, Jun, Matsuoka, Ken-Ichi, Yui, Shunsuke, Takase, Ken, Kawakita, Toshiro, Kanda, Junya, Ichinohe, Tatsuo, Atsuta, Yoshiko, Kako, Shinichi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Blood
Bone marrow transplantation
Calcineurin inhibitors
Cyclophosphamide
Cyclophosphamide - therapeutic use
Disease-Free Survival
Donors
Female
Graft versus host disease
Graft vs Host Disease - mortality
Graft vs Host Disease - prevention & control
Graft-versus-host reaction
Hematopoietic stem cells
Histocompatibility antigen HLA
HLA Antigens
Humans
Leukocytes (neutrophilic)
Lymphoma
Lymphoma - mortality
Lymphoma - therapy
Male
Middle Aged
Peripheral blood
Peripheral Blood Stem Cell Transplantation - methods
Prophylaxis
Recovery
Retrospective Studies
Siblings
Stem cell transplantation
Stem cells
Survival
Tissue Donors
Transplantation
Transplantation, Haploidentical - methods
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data comparing HLA-haploidentical donors and HLA-matched sibling donors (MSDs) in peripheral blood stem cell transplantation (PBSCT) for lymphoma are scarce. We retrospectively analyzed 465 patients with lymphoma aged 16 years or older who underwent PBSCT using haploidentical donors with post-transplant cyclophosphamide (PTCy-haplo) (n = 166) or MSDs with calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis (n = 299). Two-year overall survival (OS), progression-free survival (PFS), and GVHD-free, relapse-free survival (GRFS) in the PTCy-haplo and MSD groups were 49.2% versus 51.9% (P = 0.64), 38.0% versus 39.9% (P = 0.97), and 27.7% versus 18.5% (P = 0.006), respectively. In multivariable analyses, PTCy-haplo recipients had slower neutrophil recovery (hazard ratio [HR], 0.62; P 
ISSN:0268-3369
1476-5365
1476-5365
DOI:10.1038/s41409-024-02229-y